Version 1
: Received: 15 January 2022 / Approved: 24 January 2022 / Online: 24 January 2022 (11:19:53 CET)
How to cite:
Liu, Z.Y.; Chen, Y.C.; Wu, N.; Li, H.; Wang, J. A Pyroptosis-Related LncRNA signature in Prognosis and Immune Microenvironment infiltration Prediction of Ovarian Cancer. Preprints2022, 2022010346. https://doi.org/10.20944/preprints202201.0346.v1
Liu, Z.Y.; Chen, Y.C.; Wu, N.; Li, H.; Wang, J. A Pyroptosis-Related LncRNA signature in Prognosis and Immune Microenvironment infiltration Prediction of Ovarian Cancer. Preprints 2022, 2022010346. https://doi.org/10.20944/preprints202201.0346.v1
Liu, Z.Y.; Chen, Y.C.; Wu, N.; Li, H.; Wang, J. A Pyroptosis-Related LncRNA signature in Prognosis and Immune Microenvironment infiltration Prediction of Ovarian Cancer. Preprints2022, 2022010346. https://doi.org/10.20944/preprints202201.0346.v1
APA Style
Liu, Z.Y., Chen, Y.C., Wu, N., Li, H., & Wang, J. (2022). A Pyroptosis-Related LncRNA signature in Prognosis and Immune Microenvironment infiltration Prediction of Ovarian Cancer. Preprints. https://doi.org/10.20944/preprints202201.0346.v1
Chicago/Turabian Style
Liu, Z.Y., He Li and Jing Wang. 2022 "A Pyroptosis-Related LncRNA signature in Prognosis and Immune Microenvironment infiltration Prediction of Ovarian Cancer" Preprints. https://doi.org/10.20944/preprints202201.0346.v1
Abstract
Background: LncRNA and pyroptosis play important roles in cancer development and tumor immune microenviroment. However, pyroptosis-related lncRNAs (PRLs) in ovarian cancer have not been identified and its impact on prognosis and immune response are not fully understood. Methods: Using pearson correlation analysis, PRLs were screened. Subsequently, we constructed a prognosis signature by using LASSO cox regression. In addition, the association between risk score and cancer immune environment was analyzed. Results: In TCGA-RNA-seq cohort (n=377), 32 prognostic PRLs were selected and a 7-gene signature were developed and had high accuracy in predicting the OS of ovarian cancer patients. Stratification analysis suggested that it might serve as an independent prognostic indicator. Except to clinical outcome, the signature was significantly associated with tumor immune microenvironment. Patients with high risk score exhibited lower infiltration abundance of MHC class Ⅰ cells, Type Ⅰ IFN response and immunotherapy response. In ovarian cancer, TYMSOS was highly expressed and its high expression was associated with worse OS. TYMSOS deletion in ovarian cancer cell lines inhibited the cell proliferation, invasion and migration, indicating that it might serve as a novel biomarker in ovarian cancer. Conclusions: The prognostic PRLs signature constructed in this work is available for prognostic prediction and immune microenvironment infiltration in ovarian cancer.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
